124 related articles for article (PubMed ID: 15701341)
21. Octreoscan SPET evaluation in the diagnosis of pancreas neuroendocrine tumors.
Briganti V; Matteini M; Ferri P; Vaggelli L; Castagnoli A; Pieroni C
Cancer Biother Radiopharm; 2001 Dec; 16(6):515-24. PubMed ID: 11789028
[TBL] [Abstract][Full Text] [Related]
22. Image fusion analysis of (99m)Tc-HYNIC-Tyr(3)-octreotide SPECT and diagnostic CT using an immobilisation device with external markers in patients with endocrine tumours.
Gabriel M; Hausler F; Bale R; Moncayo R; Decristoforo C; Kovacs P; Virgolini I
Eur J Nucl Med Mol Imaging; 2005 Dec; 32(12):1440-51. PubMed ID: 16133384
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of a Correction Method for
Kanzaki T; Takahashi Y; Higuchi T; Zhang X; Mogi N; Suto T; Tsushima Y
J Nucl Med Technol; 2020 Dec; 48(4):326-330. PubMed ID: 32887762
[TBL] [Abstract][Full Text] [Related]
24. Value of image fusion using single photon emission computed tomography with integrated low dose computed tomography in comparison with a retrospective voxel-based method in neuroendocrine tumours.
Amthauer H; Denecke T; Rohlfing T; Ruf J; Böhmig M; Gutberlet M; Plöckinger U; Felix R; Lemke AJ
Eur Radiol; 2005 Jul; 15(7):1456-62. PubMed ID: 15627182
[TBL] [Abstract][Full Text] [Related]
25. Imaging neuroendocrine tumours with radiolabelled somatostatin analogues and X-ray computed tomography: a comparative study.
King CM; Reznek RH; Bomanji J; Ur E; Britton KE; Grossman AB; Besser GM
Clin Radiol; 1993 Dec; 48(6):386-91. PubMed ID: 8293643
[TBL] [Abstract][Full Text] [Related]
26. Metabolic and receptor imaging in patients with neuroendocrine tumors: comparison of fludeoxyglucose-positron emission tomography and computed tomography with indium in 111 pentetreotide.
Zalom ML; Waxman AD; Yu R; Lee J; Ih G; Wolin EM
Endocr Pract; 2009; 15(6):521-7. PubMed ID: 19491080
[TBL] [Abstract][Full Text] [Related]
27. Combined visual and quantitative assessment of somatostatin receptor scintigraphy for staging and restaging of neuroendocrine tumors.
Ueki Y; Otsuka H; Otani T; Kasai R; Otomi Y; Ikemitsu D; Azane S; Kunikane Y; Bando T; Matsuda N; Okada Y; Takayama T; Harada M
Jpn J Radiol; 2024 May; 42(5):519-535. PubMed ID: 38345724
[TBL] [Abstract][Full Text] [Related]
28. Safety and Efficacy of 68Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine Tumors.
Deppen SA; Liu E; Blume JD; Clanton J; Shi C; Jones-Jackson LB; Lakhani V; Baum RP; Berlin J; Smith GT; Graham M; Sandler MP; Delbeke D; Walker RC
J Nucl Med; 2016 May; 57(5):708-14. PubMed ID: 26769865
[TBL] [Abstract][Full Text] [Related]
29. Somatostatin receptor localization of pancreatic endocrine tumors.
Corleto VD; Scopinaro F; Angeletti S; Materia A; Basso N; Polettini E; Annibale B; Schillaci O; D'Ambra G; Marignani M; Gualdi G; Bordi C; Passaro EJ; Delle Fave G
World J Surg; 1996 Feb; 20(2):241-4. PubMed ID: 8661825
[TBL] [Abstract][Full Text] [Related]
30. Feasibility of somatostatin receptor scintigraphy in the detection of occult primary gastro-entero-pancreatic (GEP) neuroendocrine tumours.
Savelli G; Lucignani G; Seregni E; Marchianò A; Serafini G; Aliberti G; Villano C; Maccauro M; Bombardieri E
Nucl Med Commun; 2004 May; 25(5):445-9. PubMed ID: 15100502
[TBL] [Abstract][Full Text] [Related]
31. The influence of somatostatin receptor scintigraphy during preoperative staging of non-functioning pancreatic neuroendocrine tumours.
Jilesen AP; Hoefnagel SJ; Busch OR; Bennink RJ; Gouma DJ; Nieveen van Dijkum EJ
Clin Radiol; 2016 Jun; 71(6):537-42. PubMed ID: 27016111
[TBL] [Abstract][Full Text] [Related]
32. The octreotide suppression test and [111In-DTPA-D-Phe1]-octreotide scintigraphy in neuroendocrine tumours correlate with responsiveness to somatostatin analogue treatment.
Shi W; Buchanan KD; Johnston CF; Larkin C; Ong YL; Ferguson R; Laird J
Clin Endocrinol (Oxf); 1998 Mar; 48(3):303-9. PubMed ID: 9578820
[TBL] [Abstract][Full Text] [Related]
33. Comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-LAN PET/CT imaging in the same patient group with neuroendocrine tumours: preliminary results.
Demirci E; Ocak M; Kabasakal L; Araman A; Ozsoy Y; Kanmaz B
Nucl Med Commun; 2013 Aug; 34(8):727-32. PubMed ID: 23728519
[TBL] [Abstract][Full Text] [Related]
34. Somatostatin receptor imaging with indium-111-pentetreotide in gastroenteropancreatic neuroendocrine tumors: safety, efficacy and impact on patient management.
Jamar F; Fiasse R; Leners N; Pauwels S
J Nucl Med; 1995 Apr; 36(4):542-9. PubMed ID: 7699439
[TBL] [Abstract][Full Text] [Related]
35. [Diagnostic value of somatostatin receptor scintigraphy with indium-111 pentetreotide in small-cell bronchial carcinoma].
Hoefer M; Schmidt S; Welter J; Kirsch CM; Ukena D; Sybrecht GW
Pneumologie; 1998 Feb; 52(2):106-12. PubMed ID: 9557059
[TBL] [Abstract][Full Text] [Related]
36. [111In-pentetreotide in the study of tumors expressing somatostatin receptors].
Mateos Fernández J; Pons Pons F; Fuster Pelfort D; Vidal-Sicart S; Lomeña Caballero F; Herranz García-Romero R
Rev Esp Med Nucl; 1999 Oct; 18(5):325-30. PubMed ID: 10562660
[TBL] [Abstract][Full Text] [Related]
37. Primary Neuroendocrine Tumor in a Horseshoe Kidney With Positive 111In-Pentetreotide Somatostatin Receptor Scintigraphy and Negative 18F-DOPA PET/CT.
Gauthé M; Lièvre A; Alberini JL
Clin Nucl Med; 2015 Nov; 40(11):e516-7. PubMed ID: 26204216
[TBL] [Abstract][Full Text] [Related]
38. Imaging of neuroendocrine tumors: accuracy of helical CT versus SRS.
Kumbasar B; Kamel IR; Tekes A; Eng J; Fishman EK; Wahl RL
Abdom Imaging; 2004; 29(6):696-702. PubMed ID: 15162235
[TBL] [Abstract][Full Text] [Related]
39. 111In-Pentetreotide uptake in a follicular adenoma of the thyroid gland: a pitfall for 111In-Pentetreotide scintigraphy.
Yüksel M; Eziddin S; Wardelmann E; Biersack HJ
Rev Esp Med Nucl; 2006 Sep; 25(5):316-9. PubMed ID: 17173778
[TBL] [Abstract][Full Text] [Related]
40. Prediction of clinical outcome in treated neuroendocrine tumours of carcinoid type using functional volumes on 111In-pentetreotide SPECT imaging.
Gopinath G; Ahmed A; Buscombe JR; Dickson JC; Caplin ME; Hilson AJ
Nucl Med Commun; 2004 Mar; 25(3):253-7. PubMed ID: 15094443
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]